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Oncolytic viruses as cancer therapies
Stephen J Russell
Mayo Clinic
Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida
“Onco” = cancer         “lytic” = killing
Oncolytic Virotherapy: The Dream
(systemic therapy)
1 2 3
Step 1 = Infection (delivery/spread)
Step 2 = Killing infected cells
Step 3 = Killing uninfected cells
“Onco” = cancer         “lytic” = killing
virus
cancer
Oncolytic virotherapy: Big(gest) issues
















Tissue specificity of microRNAs
microRNAs are small 21-23nt regulatory RNAs mediating 
translational repression and RNA degradation. 
MicroRNA targeting: 
A versatile approach to eliminate undesired OV tropisms
Recombinant virus with 
tissue-specific miRT
In normal cell (targeted):









Kelly EJ et al., Nature Medicine, 2008
Coxsackievirus A21 (CVA21)
• (+) Sense picornavirus (enterovirus)
• Potent oncolytic activity against myeloma xenografts
• Lethal toxicity (myositis)
• Virus recovered from tumor and muscle only
CVA21s with microRNA targets
• CVA21 - miRT muscle (133/206)
• CVA21 - 142T hematopoietic
• CVA21 - 145T colon















Viability of infected cells Virus yield from infected cells
H1-HeLa cells transfected with control or muscle specific miRNA mimics
miRNA 133 & 206 offer significant protection individually
Combining miRNAs 133&206 completely blocks miRT virus toxicity and 
propagation on HeLa cells
0 102
103
In vivo tumor therapy results (IT virus)
mirT (muscle)WT CVA21No virus therapy
142T (control) 145T (control)
SURVIVAL
Advantages of microRNA targeting
1. Broadly applicable (picornavirus best, VSV worst)
2. Uses very small targeting elements (~22nt per target)





Survival ~ 5 yrs
High virus susceptibility
Highly vascular 
Low antiviral Ab titers
Suitable for IV therapy
Which Virus for Myeloma therapy?
Engineering measles for myeloma therapy
Bluming and Ziegler (1971) Lancet ii, 105-106
• Targets CD46
• Can be monitored by imaging
• Effective in mice with myeloma
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NIS
CD46 is overexpressed on human 
cancer/myeloma cells, a key determinant of 
oncolytic specificity 
Anderson et al, Cancer Res, 2004
MV-NIS
Illumination: 
the thyroidal sodium iodide symporter (NIS)
NIS concentrates cold or radioactive 
iodine (and 99mTcO4) in the thyroid gland
Radioiodine is used to destroy an 
overactive thyroid or to treat thyroid 





















KAS6/1 xenografts, 0.5 cm




































KAS6/1 xenografts, 0.5 cm


























































Phase I: 106 to 109 TCID50.
From mouse studies, need at least 
3x109
(Recently approved for 1010 and 1011
dose levels).
Myeloma cells of trial patients overexpress CD46 and are 
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Day 1 PK study (virus genome copies in blood) 
QRT-PCR results of MV-N gene (days 3-42)
P#1~P#3 106 P#4~P#6 107 P#7~P#9 108 P#10~P#12 109
blood
urine
Pre-Tx     1:10        <1:10      <1:10      <1:10        <1:10       <1:10         <1:10        <1:10     <1:10           1:10 <1:10        <1:10 
Post-Tx   1:160        1:20        1:10        1:20           1:160        1:10        <1:10         1:10       1:10            1:640        ND
sputum
Anti-MV Titers Pre- and Post- Treatment
Threshold 
for positive
May preclude repeat intravenous dosing
• Interspecies CPA comparisons demonstrated 
equivalence when dose scaled to surface area.
• When started on the day prior to virus 
administration (MV or VSV), 400 mg/m2 CPA 
Cyclophosphamide controls the humoral 
response to MV and VSV
daily for 4 days completely suppressed the 
antiviral antibody response (primary and/or 
anamnestic)
• This 4-day CPA regimen will be tested in 
combination with MV-NIS.
Baseline & day 8 123I uptake 
Patient #13, Stage 2 Dose level 1, CTX + MV-NIS 107
Day -1 123I SPECT/CT Day +8 123I SPECT/CT
Imaging spread of MV-NIS 
107 TCID50 were administered by intravenous infusion. Preceded by 
cyclophosphamide
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Efficacy requires ~ 106 TCID50 per mouse (= 3x10
9 per human)
Max dose in clinical trial to date = 109
Imaging data (4 positives) suggests viremic threshold is achievable
Recent manufacturing advances: 3x109 per ml









































MV-NIS administered 4/30 
Bloodwork on day 8 (5/7)
• M spike down 14% (6.6 to 5.7)
• IgG down 22% (9840 to 7640)
• Creatinine up (1.2 to 2.8)
• Kappa FLC up (213 to 403)














MV-NIS:  Why try other viruses?
Pre-existing immunity to MV
Childhood vaccination, natural infection
Slow intratumoral spread of MV
~10 days to max radioiodine uptake in SCID 
mice
Manufacturing/dose limitations
Max theoretical dose 1011 in 100 mls IV
Incompatibility with mice
Cannot test in syngeneic tumor models
• Nonsegmented, negative strand RNA virus of the 
Rhabdoviridae family
•Genome is approx. 11kB, composed of 5 genes
•Broad tropism but primarily a pathogen of 
cattle, hence low seroprevalence
•Favorable biological characteristics including 
rapid lytic replication cycle (10,000 progeny in 8-
12 hours) and malleable genome
Vesicular Stomatitis Virus (VSV)
•Potently oncolytic against a variety of human 
tumors
•VSV is exquisitely sensitive to the anti-viral 
cellular defences induced by interferon
Genome 
amplified















• Specificity: VSV M protein suppresses 
IFNβ production 
• VSV-IFNβ-NIS-infected cells secrete abundant 
IFN-β. This protects surrounding normal cells 
so the infection does not spread
N P M G NIS LIFN
• Tumor cells are not protected by IFNβ so the 
tumor is destroyed
• Manufacture: Not limiting; Process developed
• Immunity: No pre-existing immunity
• NIS transgene: Allows potency enhancement and 
noninvasive imaging
EM studies of VSV-IFN-NIS
VSV-XN2 = 165nm            VSV-hIFN = 190nm           VSV-hIFN-NIS = 236nm










•5TGM1 myeloma in C57Bl/6-KaLwRij mouse strain
•MPC-11 myeloma in Balb/c mice
Testing intravenous VSV-IFN-NIS in 













N P M G NIS LIFN
Daily imaging after single IV dose of VSV-IFNβ-NIS
VSV-mIFNβ-NIS: Efficacy (dose response) in 5TGM1 model: 
higher doses are more effective.
Single IV dose of VSV-mIFNβ-NIS in C57Bl6/KalwRij mice bearing 
5TGM1 myeloma tumors:
105, 106, 107, 108 dose levels, 10 animals per group 
N P M G NIS LIFNβ
High dose intravenous VSV-mIFNβ-NIS in 5TGM1 model:  
A single-shot cure.
Single intravenous dose in 5TGM1 
myeloma model
Days post 
treatment 1                2              3                4
SPECT CT imaging of intratumoral radio-isotope uptake in immune-competent C57Bl/KalwRiij 
mice bearing subcutaneous syngeneic myeloma tumors treated with VSV-IFN-NIS




Visualizing viral distribution and spread
Following treatment, harvested tumors are analyzed for Tc-99m 
uptake
•Results show multiple, punctate, foci of isotope accumulation
I.V. Treatment with VSV-mIFN-NIS
1
2
Kinetics of virus 
spread in tumors.  












Foci of infection 
spread at a rate of 
approximately 1 cell 
every 2 hours 
(radius increases by 




VSV infected cells located 
centrally within the focus of 
infection undergo cell death 
Rapid expansion and coalescence of VSV-IFN-NIS infected foci 












blood vessels infecting 




promotes viral spread 








Induction of cell death in infected 
cells. Foci expand and coalesce to 
infect large regions of tumor. 
Detectable viral gene expression
Further analysis of the single-shot cure 
scenario: role of IFNβ
5TGM1 relapse rates much higher after a single iv dose 
of VSV-human IFNβ-NIS (human IFNβ biologically 
inactive in mice)
VSV-human IFNβ-NISVSV-murine IFNβ-NISControls
So what is mouse IFNβ doing?: (i) killing tumor cells, (ii) 
inhibiting angiogenesis, or (iii) enhancing antitumor 
immunity
Further analysis of the single-shot cure 
scenario: role of IFNβ
5TGM1 relapse rates much higher after a single iv dose 
of VSV-human IFNβ-NIS (human IFNβ biologically 
inactive in mice)
VSV-human IFNβ-NISVSV-murine IFNβ-NISControls
So what is mouse IFNβ doing?: (i) killing tumor cells, (ii) 















Death of infected cells
3. MRD ERADICATION
IFNβ promotes immune 
elimination of residual 
uninfected tumor cells
VSV-hIFNβ-NIS veterinary translation
• Amy LeBlanc – Veterinarian at 
University of Tennessee
• Proposes veterinary use (companion 
dogs with multiple myeloma)
• No need to use subtherapeutic dose.  
Start with presumed effective dose
• First need tox data – ongoing 
mouse/beagle studies……..
N  P M G LNIShIfnB
NISutr utr
1.   Stop Mutations in NIS:   mIFNbeta+NIS hIFNbeta+NIS
5264 7196
VSV-IFNbeta-NIS Viruses: Manufacturing
2.   Amino acid changes 
3.   Deletions of 253 bases (5476-5728), 6 bases 3523-3528
4.   Insert leading to frameshift mutations
5.   Stop/polyadenylation changes 
Replace U with C-7U to 6U Replace C with U- 7U to 8U
3’ utr  AAUACUUUUUUU 5’ utr   CAUACUUUUUUU
AAUACCUUUUUU CAUAUUUUUUUU
VSV Production Process





















• VSV-hIFNβ approved for clinical trial 
in HCC (comprehensive tox in mice 
and rats)
• VSV-hIFNβ-NIS well tolerated in pilot 
intravenous tox studies in mice (not 
SCID) and rats. Dog study planned
Toxicology of VSV-IFN-NIS
VSV-IFNβ-NIS: Dramatic oncolytic activity is 
not seen in other murine tumor models
(i) B16 melanoma, (ii) Lewis Lung Carcinoma (LLC), (iii) 
LM-1 and (iv) ID-8 ovarian cancer, (v) EMT-6 breast 
cancer, (vi) Hepa-1 HCC.
All these cell lines are highly susceptible to VSV in tissue 
culture (equivalent to MPC11 and 5TGM1) and all form 
highly vascular subcutaneous tumors in syngeneic mice.  
BUT, in contrast to MPC11 and 5TGM1, none of these 
tumors respond to intravenous VSV-IFNβ-NIS. Virus 
infected tumor cells can be seen in day 1 explanted 
tumor, but no expanding infectious centers………..
So what are the in vivo barriers that prevent intratumoral 
spread in these models?
Virus
Asselah et al. Gut (2009)
Conclusions?
Myeloma is a great target for oncolytic virotherapy. 
MV-NIS trial has reached a meaningful dose level
Co-administration of CPA may block antiviral antibody 
response, allow repeat dosing. 
VSV-IFN-NIS may offer a single shot cure - veterinary 
testing is feasible for this virus.
GEP data may help to define best candidates (avoid 
therapy if established antiviral state)
“Onco” = cancer         “lytic” = killing
Oncolytic Virotherapy: The Dream
(systemic therapy)
1 2 3
Step 1 = Infection (delivery/spread)
Step 2 = Killing infected cells




































































































































*biopsy (if SPECT/CT positive) for QRT-PCR and IHC
optional, if previous positive
Viremia: by QRT-PCR and TCID50 of whole blood
Shedding urine and sputum: by QRT-PCR







































• Efficacy is dose-dependent in mice
– > 108 TCID50/mouse can be curative 
– (= > 4x109 TCID50/kg)
– But lower doses are effective
The width of the outer rim (infected cells that have not yet died) is 
approximately 10 cells
Since it takes 2 hours for the infectious centre to infect each successive 
layer of cells, the estimated time from infection to cell death is 20 hours 
Need for better targeting
Oncolytic viruses are targeted to tumors by 
transductional, transcriptional and physiologic 
mechanisms.
Their potency is being increased by: 
(i)   dose escalation,
(ii) rearming through virus engineering,
(iii) combination therapy with drugs that promote 
virus spread or suppress the antiviral immune 
response
Increased potency increases the risk of toxicity. 














Anti-VSV antibody response in 
VSV-IFNβ-NIS treated mice 
(Plaque Reduction Neutralization titer)
Precludes repeat intravenous dosing





Immunohistochemistry           
for MV-N Protein
*Intratumoral 99mTc %ID/g = 6.2%
Versatility of microRNA targeting
microRNA properties:
Single lineage Variable abundance




Ablate single tropism (mir125, mir122)
Ablate multiple tropisms (mirLet7a)
Target transformed component of a lineage (mir15,16)
(?microRNA-dependent viruses)


















Cancer treatment today: Imperfections
Complex





Myelosuppression, neuropathy, infection etc.
Often Not Curative
Relapse, Drug Resistance, Evolution
High risk myeloma is an ideal target for OVs
Currently incurable
Disseminated, systemic therapy required
Specificity
High expression of viral receptors eg. CD46, 
Activated signalling pathways supporting virus
propagation eg. NFkB, p53, Ras mutations






Metabolically active tumor cells
Impaired innate defences (eg interferon response)
Sluggish immune response (drugs and disease)
Killing
Highly susceptible to lytic killing by several viruses
Also (weakly) immunogenic
Illumination: Janey and 
the thyroidal sodium iodide symporter (NIS)
NIS concentrates cold or radioactive 
iodine in the thyroid gland (or 99mTcO4)
Radioiodine is used to destroy an 
overactive thyroid or to treat thyroid 
cancer after it has spread (metastasis)
Radiovirotherapy: 131I enhances MV-NIS potency
MV-NIS iv 
I-131













MM1 + MV-Edm + I-131
MM1 + MV-NIS
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